BioAtla (BCAB) Income towards Parent Company (2020 - 2026)
BioAtla (BCAB) posted quarterly Income towards Parent Company of -$9.3 million for Q1 2026, up 46.91% year-over-year from -$6.3 million in Q1 2025, and down 1.19% quarter-over-quarter from -$9.2 million in Q4 2025.
BioAtla (BCAB) Income towards Parent Company (2020 - 2026) Analysis & Trends
BioAtla's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 46.91% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$60.0 million (up 11.48% YoY), while the FY2025 annual figure was -$174.4 million, down 0.67% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$9.3 million, down from -$9.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$9.2 million in Q4 2025, with the low at -$2.8 billion in Q3 2022.
- The 5-year median for Income towards Parent Company is -$26.3 million (2025), against an average of -$219.2 million.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company sank 11403.2% in 2022, then soared 98.76% in 2023.
- BioAtla's Income towards Parent Company stood at -$27.9 million in 2022, then grew by 2.65% to -$27.2 million in 2023, then soared by 42.24% to -$15.7 million in 2024, then surged by 41.5% to -$9.2 million in 2025, then dropped by 1.19% to -$9.3 million in 2026.
- Business Quant data shows BCAB's Income towards Parent Company at -$9.3 million in Q1 2026, -$9.2 million in Q4 2025, and -$15.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.88 Mn |
| Mar 31, 2026 | -9.29 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -15.28 Mn |
| Jun 30, 2025 | -26.27 Mn |
| Mar 31, 2025 | -17.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -11.85 Mn |
| Jun 30, 2024 | -22.77 Mn |
| Mar 31, 2024 | -472.87 Mn |
| Dec 31, 2023 | -27.17 Mn |
| Sep 30, 2023 | -34.13 Mn |
| Jun 30, 2023 | -133.99 Mn |
| Mar 31, 2023 | -27.86 Mn |
| Dec 31, 2022 | -27.91 Mn |
| Sep 30, 2022 | -2.76 Bn |
| Jun 30, 2022 | -91.08 Mn |
| Mar 31, 2022 | -24.64 Mn |
| Dec 31, 2021 | -24.76 Mn |
| Sep 30, 2021 | -23.99 Mn |